TheEdgeResearch
Home / Stocks / NVAX

Novavax, Inc. (NVAX)

NASDAQ Healthcare Biotechnology
$7.47 ▼ -3.24%
Market Cap
$1.23B
Sector
Healthcare
Industry
Biotechnology
Beta
2.72
52-Wk Range
6.36-13.39
CEO
John Charles Jacobs
Country
US
Currency
USD

Novavax, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Gaithersburg, MD, US. The stock last traded at $7.47, down 3.24% on the session, giving a market capitalisation of $1.23B. On trailing twelve-month figures it carries a trailing P/E of -16.24, a net margin of -18.6%. Its beta of 2.72 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-16.24
Price / Sales
2.99
Price / Book
-5.68
EV / EBITDA
-36.44
Gross margin
77.3%
Operating margin
-19.6%
Net margin
-18.6%
Return on equity
—
Debt / equity
-1.36
Current ratio
2.15
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
749
IPO date
1995-12-05
Headquarters
Gaithersburg, MD, US
About Novavax, Inc.

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Comparable companies

Novavax, Inc. is most often compared with the following Healthcare names:

ARCTBNTXEBSGOVXINOMRNAOGENPCVXSCNIVALN
More research on NVAX
NVAX technical analysis NVAX TheEdge Score Compare against peers
Open full interactive analysis & DCF →